• In early August 2026, Zevra Therapeutics reported Q2 2026 results showing higher sales of US$39.66 million alongside lower net income of US$8.75 million compared with the prior year, while also highlighting strong US uptake of its Niemann-Pick disease type C therapy MIPLYFFA (arimoclomol).
• A separate publication of four-year, real-world data on arimoclomol in a broad Niemann-Pick disease type C population, including adults, adds clinically rich evidence that extends beyond prior pivotal trial results and may be important for physicians and regulators assessing the drug’s role in care.
• With these developments and recent share price moves, we’ll examine how growing real-world evidence for MIPLYFFA shapes Zevra’s investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Zevra Therapeutics' Investment Narrative?

To own Zevra today, you really have to believe that MIPLYFFA can anchor a focused rare‑disease business while management manages regulatory and execution risk. The Q2 2026 print reinforces that story in the US, with revenue of US$39.66 million helped by strong MIPLYFFA uptake, even as net income stepped down from last year’s one‑off‑boosted levels. The new four‑year real‑world arimoclomol data slots directly into the most important near‑term catalyst: the European re‑examination following July’s negative EMA opinion. If regulators view these data as clinically meaningful, the Europe opportunity could look different from what recent headlines imply; if not, Zevra is more reliant on the US NPC franchise and its pipeline. Recent share price swings, despite a low earnings multiple and prior profitability, underline how sensitive the stock is to those binary regulatory calls and to any sign of slowing MIPLYFFA momentum.

However, the EMA setback and ongoing legal scrutiny remain key risks investors should watch closely. Zevra Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Eleven Simply Wall St Community fair value estimates run from about US$12 to over US$82 per share, reflecting very different expectations. Set that against the recent EMA setback and Zevra’s reliance on MIPLYFFA, and you can see why it pays to compare several viewpoints before deciding how those risks and potential rewards balance out.

Explore 11 other fair value estimates on Zevra Therapeutics - why the stock might be worth just $12.05!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zevra Therapeutics research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Zevra Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zevra Therapeutics' overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.